Business Context and Reporting Period
This Form 8-K, dated November 16, 2020, reports the effective date of the Amended Joint Plan of Reorganization for BioRestorative Therapies, Inc. (the "Company"). The Company filed for Chapter 11 bankruptcy on March 20, 2020. On November 16, 2020, the Plan became effective following a Confirmation Order entered by the Bankruptcy Court on October 30, 2020.
Key Financial Metrics and Capital Structure
The filing details significant capital restructuring and funding events rather than standard operating financial metrics like revenue or profit, which are not provided in this document.
- Funding Received: Auctus Fund, LLC provided $3,500,000 in initial funding. Four other lenders provided approximately $348,000. Auctus is obligated to provide additional funding of $3,500,000 less the DIP Obligation (approx. $1,200,000) and DIP Costs.
- Debt Instruments Issued:
- Secured Convertible Notes: Issued in principal amounts equal to the Funding (110% for Auctus). Terms include a 3-year maturity, 7% annual interest, and mandatory conversion upon listing on a senior exchange.
- Unsecured Convertible Notes: Issued to holders of allowed general unsecured claims (Auctus and Other Lenders) in the amount of their claims. Terms include a 3-year maturity, 5% annual interest, and mandatory conversion upon listing.
- Equity Issuance:
- Common Stock: 1,639,203,270 shares were outstanding as of the Effective Date. An additional 1,049,726,797 shares were issued to general unsecured claim holders. Specific shares were issued to Desmarais and Tuxis Trust in exchange for claims.
- Warrants: Class A Warrants (exercise price $0.0005) and Class B Warrants (exercise price $0.001) were issued. Approximately 15.2 billion shares are issuable pursuant to these warrants, subject to antidilution provisions.
- Authorized Capital: The Company increased authorized Common Stock to 300,000,000,000 shares and reduced par value to $0.0001 per share.
Material Changes Versus Prior Period
The filing represents a fundamental change in the Company's capital structure and governance resulting from the Chapter 11 reorganization:
- Debt-to-Equity Conversion: Significant portions of existing debt, including the DIP Obligation and general unsecured claims, were exchanged for new secured/unsecured convertible notes and common stock.
- Shareholder Dilution: The issuance of over 1 billion shares to unsecured creditors and billions of shares underlying warrants represents a massive increase in potential share count compared to the pre-bankruptcy period.
- Management Turnover: The entire previous board and executive leadership resigned. Mark Weinreb (former CEO/Chairman) and three other directors stepped down.
- Liquidity Event: The Company received immediate cash funding of approximately $3.85 million from Auctus and other lenders to support post-bankruptcy operations.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The filing contains forward-looking statements regarding future financings and operations. The Company anticipates listing its Common Stock on the Nasdaq Capital Market or another senior exchange, which would trigger the mandatory conversion of outstanding convertible notes.
Risks and Contingencies:
- Financing Conditions: Additional funding from Auctus is subject to certain conditions.
- Market Risks: Risks related to trading on the OTC Pink Market and share price volatility.
- Leak-out Restrictions: New shareholders and note holders are subject to restrictions on selling shares (e.g., 33% per 30-day period for general unsecured claim holders; 16.6% per 30-day period for Auctus/Other Lenders upon conversion).
- Antidilution: The number of shares issuable under warrants is subject to increase based on antidilution protection provisions.
Investor Verification Checklist
- Verify the exact amount of additional funding Auctus is obligated to provide after deducting the DIP Obligation and costs.
- Confirm the current trading status of the Common Stock and whether the mandatory conversion trigger (listing on a senior exchange) has been met.
- Review the specific terms of the "leak-out restrictions" to understand liquidity constraints for new shareholders.
- Assess the impact of the 300 billion authorized shares and the billions of warrant shares on future dilution.
- Examine the background and track record of the new CEO, Lance Alstodt, and the new board composition.